Aptose presented clinical data for tuspetinib triple drug therapy at ASH Annual Meeting
High rate of clinical responses in newly diagnosed AML patients
Safety highlighted as a notable feature of the therapy
Safety and Efficacy
TUS+VEN+AZA triplet therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations.
Clinical Responses
100% response rate observed at the higher TUS dose levels, including FLT3 wildtype subjects and AML with adverse mutations.
MRD Negativity
78% of responding subjects achieved MRD negativity by central flow cytometry.
Therapy Tolerance
TUS+VEN+AZA triplet therapy well tolerated with no dose-limiting toxicities reported.
New Treatment Level
Promising early responses seen at the recently enrolled 160 mg TUS dose level.
- TUS+VEN+AZA therapy shows promising safety and efficacy in AML patients
- Targets diverse mutations and achieves high clinical response rates
- Significant MRD negativity observed in responding subjects
- Therapy well tolerated with no dose-limiting toxicities
Tuspetinib, as part of the triple drug therapy, addresses AML's unmet needs with high response rates and safety profile. Aptose's innovative approach aims to provide effective treatment to a broad range of AML patients.